Natural combination hormone replacement formulations and therapies
AssigneeTherapeuticsMD, Inc.
InventorsBrian A. Bernick, Janice Louise Cacace, Peter H.R. Persicaner, Neda Irani, Julia M. Amadio
Life of this patent
Estimating the term…
Abstract
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Claims16
(canceled)
A pharmaceutical composition comprising:
- solubilized estradiol;
- suspended progesterone;
- and a solubilizing agent;
- wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and progesterone are uniformly dispersed;
- wherein at least about 90% of the estradiol is solubilized in the solubilizing agent;
- and
- wherein the solubilizing agent comprises predominately a saturated C6-C12 oil.
A pharmaceutical composition comprising:
- solubilized estradiol;
- suspended progesterone;
- and
- a solubilizing agent, the solubilizing agent comprising predominately a saturated C6-C12 oil;
- wherein the estradiol and the suspended progesterone are present in the solubilizing agent, the estradiol and progesterone are uniformly dispersed, and at least about 90% of the estradiol is solubilized in the solubilizing agent;
- and
- wherein the estradiol does not precipitate for at least 14 days.
A method of treating menopause symptoms in a woman with a uterus comprising:
- administering an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising solubilized estradiol, suspended progesterone, and a solubilizing agent;
- wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent, the estradiol and the suspended progesterone are uniformly dispersed and at least about 90% of the estradiol is solubilized in the solubilizing agent;
- and
- wherein the solubilizing agent comprises predominately a saturated C6-C12 oil.
Dependencies are inferred from the claim text.